MedTrace Logo

The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia

NCT04076371 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1640

Last updated 2019-09-03

No results posted yet for this study

Summary

A randomized, double-blind trial of the treatment effect of dose-low antipsychotics combined with low-dose sertraline in 1640 schizophrenia patients

Conditions

Interventions

DRUG

olanzapine-sertraline combination

the patient was prescribed low-dose olanzapine (7.5-10mg/day) combined with low-dose sertraline (50-100mg/day)

DRUG

only olanzapine

the patient was prescribed moderate to severity dose of olanzapine (12.5-20mg/day)

DRUG

risperidone-sertraline combination

the patient was prescribed low-dose risperidone (2-3.5mg/day) combined with low-dose sertraline (50-100mg/day)

DRUG

only risperidone

the patient was prescribed moderate to severity dose of risperidone (4-6mg/day)

DRUG

paliperidone-sertraline combination

the patient was prescribed low-dose paliperidone (3-4.5mg/day) combined with low-dose sertraline (50-100mg/day)

DRUG

only paliperidone

the patient was prescribed moderate to severity dose of paliperidone (6-9mg/day)

DRUG

ziprasidone-sertraline combination

the patient was prescribed low-dose ziprasidone (60-100mg/day) combined with low-dose sertraline (50-100mg/day)

DRUG

only ziprasidone

the patient was prescribed moderate to severity dose of ziprasidone (120-160mg/day)

Sponsors & Collaborators

  • Beijing HuiLongGuan Hospital

    lead OTHER

Principal Investigators

  • Xiaoe Lang, Doctor · The First Affiliated Hospital of Shanxi Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2018-12-31
Completion
2018-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04076371 on ClinicalTrials.gov